Scotland backs diabetes drug

People in Scotland with type-2 diabetes now have access to a wider choice of treatments after saxagliptin (Onglyza) was accepted for use within NHS Scotland.

The Scottish Medicine Consortium approved restricted use of the drug in adult patients with type-2 diabetes as an add-on combination therapy with metformin, when metformin plus exercise does not achieve adequate glycaemic control.

The dipeptidyl peptidase4 inhibitor is restricted to use when the addition of sulphonylureas is not deemed to be appropriate.

Its use represents an alternative to other agents such as thiazolidinediones, the SMC said in a statement.

However, the SMC said it could not recommend the use of saxagliptin in combination with sulphonylureas or thiazolidinediones.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in